Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etrinabdione
- Development stage
- Phase 2
- Lead developer
- Emerald Health Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Etrinabdione (VCE-004.8) is a semi-synthetic cannabidiol (CBD) derivative and aminoquinone compound developed as an orally active small molecule drug. It acts as a dual agonist of peroxisome proliferator-activated receptor gamma (PPARγ) and cannabinoid receptor type 2 (CB2), with additional activity on the hypoxia-inducible factor pathway and B55α/AMPK/Sirtuin 1/eNOS signaling axis[1][3][6]. These mechanisms confer potent anti-inflammatory, antifibrotic, neuroprotective, angiogenic, and vasculoprotective effects. Etrinabdione has demonstrated efficacy in preclinical models of multiple sclerosis, scleroderma/systemic sclerosis, ischemic stroke, critical limb ischemia/peripheral artery disease (PAD), and fibrosis by reducing inflammation and promoting tissue repair[1][4][6]. The oral formulation is known as EHP-101.
- Brand names
- EHP-101EHP101EHP 101
- Other names
- VCE-004.8VCE004.8VCE 004.8etrinabdione
02
Targets
CNR2 (Cannabinoid receptor type 2)PPARG (Peroxisome proliferator-activated receptor gamma)HIF axis (Hypoxia signaling family)PPP2R2A (PP2A regulatory subunit B55 alpha)
Beyond the preview
Go deeper on etrinabdione.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etrinabdione.